Top Markets
Coin of the day
Asensus Surgical, Inc. Asensus Surgical, Inc.

Asensus Surgical, Inc.

ASXC
Rangering i aksjer #22069
Asensus Surgical, Inc., a medical technology enterprise established in 2006 and... Asensus Surgical, Inc., a medical technology enterprise established in 2006 and headquartered in Durham, North Carolina, focuses on the research, development, and commercialization of robotic medical devices. Its core mission is to elevate minimally invasive surgical procedures throughout the United States, Europe, and Asia through innovative robotic solutions. The company's unique approach involves digitally bridging the gap between surgeons and patients, thereby introducing a new paradigm of "Performance-Guided surgery." This system aims to equip surgeons with critical clinical intelligence, ensuring consistently superior patient outcomes and setting a higher benchmark for surgical standards. Key products include the Senhance Surgical system, a multi-port robotic platform that can maneuver up to four arms to precisely control surgical instruments and a camera during laparoscopic operations. Their product line also features a range of specialized instruments, such as 3mm diameter instruments, 3mm and 5mm hooks, and articulating tools. Additionally, they offer the Senhance ultrasonic system, an advanced energy device designed for accurate, controlled tissue ligation and division. The company, initially known as TransEnterix, Inc., officially rebranded to Asensus Surgical, Inc. in February 2021.
Aksjekurs
$0.3479
Sist synkronisert: 2024-08-21
Markedsverdi
$94.92M
Endring (1 dag)
0.64%
Endring (1 år)
0.00%
Land
US
Handel Asensus Surgical, Inc. (ASXC)

Kategori

P/E-forhold for Asensus Surgical, Inc. (ASXC)
P/E-forhold per August 2026 TTM: -1.12
Ifølge Asensus Surgical, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -1.12. Ved slutten av 2022 hadde selskapet en P/E på -1.09.
P/E-forholdshistorikk for Asensus Surgical, Inc. fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -1.12 10.03%
2023 -1.02 -6.55%
2022 -1.09 -73.06%
2021 -4.03 436.27%
2020 -0.75 344.77%
2019 -0.17 -97.77%
2018 -7.58 -70.59%
2017 -25.77 63.11%
2016 -15.80 -71.10%
2015 -54.68 -7.31%
2014 -58.99 145.02%
2013 -24.08 2,000.38%
2012 -1.15 -93.96%
2011 -18.97 -59.05%
2010 -46.32 -24.93%
2009 -61.70 138.25%
2008 -25.90 -79.37%
2007 -125.51 697.41%
2006 -15.74 -93.04%
2005 -226.30 734.28%
2004 -27.13 144.54%
2003 -11.09 491.04%
2002 -1.88 -103.36%
2001 55.84 240.83%
2000 16.38 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
35.77 -3,287.64%
US
34.86 -3,206.33%
US
21.39 -2,005.71%
IE
20.90 -1,962.18%
US
- -
DE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.